Serapha Bio takes flight from Boundless merger with $230M and gene-editing prospect from China on June 24, 2026 alpha 1-Antitrypsin Deficiency Base Editing Boundless Bio China Gene Modification in vivo Nasdaq Piperine Extract (Standardized) reverse merger Rheumatoid Arthritis Serapha Bio SERP-01 SERPINA1 gene YolTech +
Boundless Bio agrees to reverse merger with Serapha Bio in $230M gene‑editing deal on June 23, 2026 alpha 1-Antitrypsin Deficiency Boundless Bio Capital Management cash dividend Gene Modification Investments Nasdaq Piperine Extract (Standardized) reverse merger Rheumatoid Arthritis RTW Serapha Bio Series A surge +
Obsidian Therapeutics Goes Public Through Galera Reverse Merger with $350M PIPE Financing on April 15, 2026 financing characteristics Galera Therapeutics Obsidian Therapeutics OBX-115 Piperine Extract (Standardized) reverse merger TIL cell therapy +